Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 12 de 12
Filtrar
1.
J Cell Mol Med ; 22(9): 4496-4506, 2018 09.
Artigo em Inglês | MEDLINE | ID: mdl-29993187

RESUMO

Aplastic anaemia (AA) is a life-threatening hematopoietic disorder characterized by hypoplasia and pancytopenia with increasing fat cells in the bone marrow (BM). The BM-derived mesenchymal stem cells (MSCs) from AA are more susceptible to be induced into adipogenic differentiation compared with that from control, which may be causatively associated with the fatty BM and defective hematopoiesis of AA. Here in this study, we first demonstrated that levamisole displayed a significant suppressive effect on the in vitro adipogenic differentiation of AA BM-MSCs. Mechanistic investigation revealed that levamisole could increase the expression of ZFP36L1 which was subsequently demonstrated to function as a negative regulator of adipogenic differentiation of AA BM-MSCs through lentivirus-mediated ZFP36L1 knock-down and overexpression assay. Peroxisome proliferator-activated receptor gamma coactivator 1 beta (PPARGC1B) whose 3'-untranslated region bears adenine-uridine-rich elements was verified as a direct downstream target of ZFP36L1, and knock-down of PPARGC1B impaired the adipogenesis of AA BM-MSCs. Collectively, our work demonstrated that ZFP36L1-mediated post-transcriptional control of PPARGC1B expression underlies the suppressive effect of levamisole on the adipogenic differentiation of AA BM-MSCs, which not only provides novel therapeutic targets for alleviating the BM fatty phenomenon of AA patients, but also lays the theoretical and experimental foundation for the clinical application of levamisole in AA therapy.


Assuntos
Adipócitos/efeitos dos fármacos , Adipogenia/efeitos dos fármacos , Anemia Aplástica/genética , Fator 1 de Resposta a Butirato/genética , Proteínas de Transporte/genética , Levamisol/farmacologia , Células-Tronco Mesenquimais/efeitos dos fármacos , Adipócitos/metabolismo , Adipócitos/patologia , Adipogenia/genética , Adolescente , Adulto , Anemia Aplástica/metabolismo , Anemia Aplástica/patologia , Células da Medula Óssea/efeitos dos fármacos , Células da Medula Óssea/metabolismo , Células da Medula Óssea/patologia , Fator 1 de Resposta a Butirato/agonistas , Fator 1 de Resposta a Butirato/metabolismo , Proteínas de Transporte/metabolismo , Estudos de Casos e Controles , Diferenciação Celular , Feminino , Regulação da Expressão Gênica , Genes Reporter , Humanos , Luciferases/genética , Luciferases/metabolismo , Masculino , Células-Tronco Mesenquimais/metabolismo , Células-Tronco Mesenquimais/patologia , Pessoa de Meia-Idade , Cultura Primária de Células , Proteínas de Ligação a RNA , Transdução de Sinais
2.
Histochem Cell Biol ; 139(4): 525-34, 2013 Apr.
Artigo em Inglês | MEDLINE | ID: mdl-23160625

RESUMO

WASP homolog associated with actin, membranes and microtubules (WHAMM) is a newly discovered nucleation-promoting factor that links actin and microtubule cytoskeleton and regulates transport from the endoplasmic reticulum to the Golgi apparatus. However, knowledge of WHAMM is limited to interphase somatic cells. In this study, we examined its localization and function in mouse oocytes during meiosis. Immunostaining showed that in the germinal vesicle (GV) stage, there was no WHAMM signal; after meiosis resumption, WHAMM was associated with the spindle at prometaphase I (Pro MI), metaphase I (MI), telophase I (TI) and metaphase II (MII) stages. Nocodazole and taxol treatments showed that WHAMM was localized around the MI spindle. Depletion of WHAMM by microinjection of specific short interfering (si)RNA into the oocyte cytoplasm resulted in failure of spindle migration, disruption of asymmetric cytokinesis and a decrease in the first polar body extrusion rate during meiotic maturation. Moreover, actin cap formation was also disrupted after WHAMM depletion, confirming the failure of spindle migration. Taken together, our data suggest that WHAMM is required for peripheral spindle migration and asymmetric cytokinesis during mouse oocyte maturation.


Assuntos
Proteínas de Transporte/metabolismo , Citocinese , Microtúbulos/metabolismo , Oócitos/citologia , Oócitos/metabolismo , Fuso Acromático/metabolismo , Animais , Transporte Biológico , Proteínas de Transporte/genética , Proteínas de Ciclo Celular , Células Cultivadas , Proteínas do Citoesqueleto , Retículo Endoplasmático/metabolismo , Feminino , Complexo de Golgi/metabolismo , Meiose , Camundongos , Camundongos Endogâmicos ICR , Nocodazol/farmacologia , Paclitaxel/farmacologia , Interferência de RNA , RNA Interferente Pequeno , Moduladores de Tubulina/farmacologia
3.
Eur J Clin Invest ; 42(5): 517-25, 2012 May.
Artigo em Inglês | MEDLINE | ID: mdl-22023453

RESUMO

BACKGROUND: Hepcidin plays a central role in iron homeostasis, which is regulated by iron stores, the rate of erythropoiesis, inflammation, and hypoxia. Aberrant expression of hepcidin was found in many diseases, however, there is scant information on hepcidin expression in acute leukemia (AL). MATERIALS AND METHODS: 32 patients with AL which diagnosis according to FAB criteria were studied. Serum hepcidin levels, erythropoietin (EPO), interleukin-6 (IL-6), hematological parameters, intracellular and extracellular iron store were evaluated. RESULTS: Hepcidin was elevated significantly with increased iron storage in patients at onset of AL when erythropoiesis was depressed by blast cells, then decreased significantly with AL remission, while soluble transferrin receptor (sTfR) concentration was elevated. Negative correlations were found between serum hepcidin and erythropoietic markers including RBC, Hb, Ret and sTfR. Positive correlations were shown between hepcidin and ferritin, between hepcidin and ratio of sideroblasts, as well as between hepcidin and IL-6. CONCLUSIONS: Hepcidin production was regulated by iron stores, inflammation and erythropoietic activity in AL patients. Erythropoietic activity may play the main role among the regulators of hepcidin expresssion.


Assuntos
Peptídeos Catiônicos Antimicrobianos/sangue , Eritropoese/fisiologia , Leucemia/sangue , Adulto , Eritropoetina/sangue , Feminino , Ferritinas/sangue , Hepcidinas , Humanos , Interleucina-6/sangue , Masculino , Pessoa de Meia-Idade , Receptores da Transferrina/metabolismo , Estatística como Assunto , Transferrina/metabolismo , Adulto Jovem
4.
Curr Med Sci ; 42(3): 561-568, 2022 Jun.
Artigo em Inglês | MEDLINE | ID: mdl-35678917

RESUMO

OBJECTIVE: To evaluate the impact of hypertension on the clinical outcome of COVID-19 patients aged 60 years old and older. METHODS: This single-center retrospective cohort study enrolled consecutive COVID-19 patients aged 60 years old and older, who were admitted to Liyuan Hospital from January 1, 2020 to April 25, 2020. All included patients were divided into two groups: hypertension and nonhypertension group. The baseline demographic characteristics, laboratory test results, chest computed tomography (CT) images and clinical outcomes were collected and analyzed. The prognostic value of hypertension was determined using binary logistic regression. RESULTS: Among the 232 patients included in the analysis, 105 (45.3%) patients had comorbid hypertension. Compared to the nonhypertension group, patients in the hypertension group had higher neutrophil-to-lymphocyte ratios, red cell distribution widths, lactate dehydrogenase, high-sensitivity C-reactive protein, D-dimer and severity of lung lesion, and lower lymphocyte counts (all P<0.05). Furthermore, the hypertension group had a higher proportion of intensive care unit admissions [24 (22.9%) vs. 14 (11.0%), P=0.02) and deaths [16 (15.2%) vs. 3 (2.4%), P<0.001] and a significantly lower probability of survival (P<0.001) than the nonhypertension group. Hypertension (OR: 4.540, 95% CI: 1.203-17.129, P=0.026) was independently correlated with all-cause in-hospital death in elderly patients with COVID-19. CONCLUSION: The elderly COVID-19 patients with hypertension tend to have worse conditions at baseline than those without hypertension. Hypertension may be an independent prognostic factor of poor clinical outcome in elderly COVID-19 patients.


Assuntos
COVID-19 , Hipertensão , Idoso , COVID-19/complicações , Mortalidade Hospitalar , Humanos , Hipertensão/complicações , Hipertensão/epidemiologia , Pessoa de Meia-Idade , Estudos Retrospectivos , SARS-CoV-2
5.
Reproduction ; 141(4): 417-24, 2011 Apr.
Artigo em Inglês | MEDLINE | ID: mdl-21273367

RESUMO

Maternal diabetes adversely affects preimplantation embryo development and oocyte maturation. Thus, it is important to identify ways to eliminate the effects of maternal diabetes on preimplantation embryos and oocytes. The objectives of this study were to investigate whether islet transplantation could reverse the effects of diabetes on oocytes. Our results revealed that maternal diabetes induced decreased ovulation; increased the frequency of meiotic spindle defects, chromosome misalignment, and aneuploidy; increased the relative expression levels of Mad2 and Bub1; and enhanced the sensitivity of oocytes to parthenogenetic activation. Islet transplantation prevented these detrimental effects. Therefore, we concluded that islet transplantation could reverse the effects of diabetes on oocytes, and that this technique may be useful to treat the fundamental reproductive problems of women with diabetes mellitus.


Assuntos
Transplante das Ilhotas Pancreáticas/fisiologia , Oócitos/fisiologia , Gravidez em Diabéticas/terapia , Efeitos Tardios da Exposição Pré-Natal/prevenção & controle , Aneuploidia , Animais , Glicemia/análise , Glicemia/fisiologia , Peso Corporal , Aberrações Cromossômicas/embriologia , Aberrações Cromossômicas/estatística & dados numéricos , Diabetes Mellitus Experimental/sangue , Diabetes Mellitus Experimental/induzido quimicamente , Diabetes Mellitus Experimental/fisiopatologia , Diabetes Mellitus Experimental/terapia , Feminino , Camundongos , Camundongos Endogâmicos C57BL , Oócitos/metabolismo , Oócitos/patologia , Ovulação/fisiologia , Gravidez , Gravidez em Diabéticas/sangue , Gravidez em Diabéticas/patologia , Gravidez em Diabéticas/fisiopatologia , Efeitos Tardios da Exposição Pré-Natal/genética , Fuso Acromático/genética , Fuso Acromático/metabolismo , Fuso Acromático/patologia , Estreptozocina
6.
Zhongguo Shi Yan Xue Ye Xue Za Zhi ; 26(6): 1632-1636, 2018 Dec.
Artigo em Zh | MEDLINE | ID: mdl-30501696

RESUMO

OBJECTIVE: To investigate the exprassion of WT1 gene in patients with adult acute myeloid leukemia (AML) and its clinical significance. METHODS: Sixty-three newly diagnosed patients with acute myeloid leukemia were selected. Quantitative RT-PCR was used to detect the expression of WT1 gene in the 63 AML patients and 20 non-AML controls. RESULTS: WT1 gene was highly expressed in AML patents and its expression in the low-risk group was significantly lower than that in middle-risk group and high-risk group (P<0.05), and no significant difference of WT1 gene expression between middle-risk and high-risk group was observed. In the patients of middle-risk and high-risk patients, the expression of WT1 gene in the remission group was significantly lower than that in the patients of non-remission after treatment (P<0.05). The non-remission patients after first treatment in middle-risk and high-risk group were treated with second induction therapy. After second induction therapy, the WT1 expression in remission patients was significantly decreased (P<0.05) in comparison with that in patients still in non-remission. There was a negative correlation between WT1 expression and the 2-year overall survival rate in the newly diagnosed middle and high-risk AML patients. CONCLUSION: The detection of WT1 gene expression can help to divide AML patients into low-/middle-/high-risk groups and to evaluate therapeutic response and clinical prognosis in middle and high-risk AML patients.


Assuntos
Leucemia Mieloide Aguda , Doença Aguda , Expressão Gênica , Humanos , Neoplasia Residual , Prognóstico , Proteínas WT1
7.
J Neuroimmunol ; 283: 1-6, 2015 Jun 15.
Artigo em Inglês | MEDLINE | ID: mdl-26004148

RESUMO

Guillain-Barré syndrome (GBS) is a post-infectious autoimmune disease. Dendritic cells (DCs) can recognize the pathogen and modulate the host immune response. Exploring the role of DCs in GBS will help our understanding of the disease development. In this study, we aimed to analyze plasmacytoid and conventional DCs in peripheral blood of patients with GBS at different stages of the disease: acute phase as well as early and late recovery phases. There was a significant increase of plasmacytoid DCs in the acute phase (p=0.03 vs healthy donors). There was a positive correlation between percentage of plasmacytoid DCs and the clinical severity of patients with GBS (r=0.61, p<0.001). Quantitative polymerase chain reaction and flow cytometry confirmed the aberrant plasmacytoid DCs in GBS. Thus, plasmacytoid DCs may participate in the development of GBS.


Assuntos
Células Dendríticas/imunologia , Síndrome de Guillain-Barré/imunologia , Doença Aguda , Adolescente , Adulto , Idoso , Idoso de 80 Anos ou mais , Antígenos CD/biossíntese , Antígenos CD/genética , Autoanticorpos/sangue , Autoanticorpos/imunologia , Autoantígenos/imunologia , Convalescença , Feminino , Citometria de Fluxo , Gangliosídeos/imunologia , Síndrome de Guillain-Barré/sangue , Síndrome de Guillain-Barré/genética , Síndrome de Guillain-Barré/fisiopatologia , Síndrome de Guillain-Barré/terapia , Humanos , Imunoglobulina G/sangue , Imunoglobulinas Intravenosas/uso terapêutico , Masculino , Pessoa de Meia-Idade , Condução Nervosa , Troca Plasmática , Índice de Gravidade de Doença , Receptor 7 Toll-Like/biossíntese , Receptor 7 Toll-Like/genética , Receptor Toll-Like 9/biossíntese , Receptor Toll-Like 9/genética , Regulação para Cima , Adulto Jovem
8.
Stem Cells Dev ; 24(15): 1793-804, 2015 Aug 01.
Artigo em Inglês | MEDLINE | ID: mdl-25867817

RESUMO

Mesenchymal stem cell (MSC) differentiation is dramatically reduced after long-term in vitro culture, which limits their application. MSCs derived from induced pluripotent stem cells (iPSCs-MSCs) represent a novel source of MSCs. In this study, we investigated the therapeutic effect of iPSC-MSCs on diabetic mice. Streptozocin-induced diabetic mice transplanted with 400 islets alone or with 1×10(6) iPSC-MSCs were examined following rapamycin injection (0.1 mg/kg/day, i.p., from days 0 to 9) after transplantation. Our results showed that iPSC-MSCs combined with rapamycin significantly prolonged islet allograft survival in the diabetic mice; 50% of recipients exhibited long-term survival (>100 days). Histopathological analysis revealed that iPSC-MSCs combined with rapamycin preserved the graft effectively, inhibited inflammatory cell infiltration, and resulted in substantial release of insulin. Flow cytometry results showed that the proportion of CD4(+) and CD8(+) T cells was significantly reduced, and the number of T regulatory cells increased in the spleen and lymph nodes in the iPSC-MSCs combined with the rapamycin group compared with the rapamycin-alone group. Production of the Th1 proinflammatory cytokines interleukin-2 (IL-2) and interferon-γ was reduced, and secretion of the anti-inflammatory cytokines IL-10 and transforming growth factor-ß was enhanced compared with the rapamycin group, as determined using enzyme-linked immunosorbent assays. Transwell separation significantly weakened the immunosuppressive effects of iPSC-MSCs on the proliferation of Con A-treated splenic T cells, which indicated that the combined treatment exerted immunosuppressive effects through cell-cell contact and regulation of cytokine production. Taken together, these findings highlight the potential application of iPSC-MSCs in islet transplantation.


Assuntos
Diferenciação Celular/imunologia , Células-Tronco Pluripotentes Induzidas , Transplante das Ilhotas Pancreáticas , Sirolimo/farmacologia , Linfócitos T Reguladores/imunologia , Células Th1/imunologia , Tolerância ao Transplante , Aloenxertos , Animais , Relação Dose-Resposta a Droga , Feminino , Células-Tronco Pluripotentes Induzidas/imunologia , Células-Tronco Pluripotentes Induzidas/transplante , Camundongos , Camundongos Endogâmicos BALB C
9.
Diabetes ; 63(10): 3458-69, 2014 Oct.
Artigo em Inglês | MEDLINE | ID: mdl-24834979

RESUMO

Islet transplantation is a therapeutic option for type 1 diabetes, but its long-term success is limited by islet allograft survival. Many factors imperil islet survival, especially the adverse effects and toxicity due to clinical immunosuppressants. Compound (Cpd) K is a synthesized analog of highly unsaturated fatty acids from Isatis tinctoria L. (Cruciferae). Here we investigated the therapeutic effect of Cpd K in diabetic mice and found that it significantly prolonged islet allograft survival with minimal adverse effects after 10 days. Furthermore, it reduced the proportion of CD4(+) and CD8(+) T cells in spleen and lymph nodes, inhibited inflammatory cell infiltration in allografts, suppressed serum interleukin-2 and interferon-γ secretion, and increased transforming growth factor-ß and Foxp3 mRNA expression. Surprisingly, Cpd K and rapamycin had a synergistic effect. Cpd K suppressed proliferation of naïve T cells by inducing T-cell anergy and promoting the generation of regulatory T cells. In addition, nuclear factor-κB signaling was also blocked. Taken together, these findings indicate that Cpd K may have a potential immunosuppressant effect on islet transplantation.


Assuntos
Diabetes Mellitus Experimental/cirurgia , Ginsenosídeos/uso terapêutico , Sobrevivência de Enxerto/efeitos dos fármacos , Imunossupressores/uso terapêutico , Transplante das Ilhotas Pancreáticas , Animais , Linfócitos T CD4-Positivos/efeitos dos fármacos , Linfócitos T CD4-Positivos/patologia , Linfócitos T CD8-Positivos/efeitos dos fármacos , Linfócitos T CD8-Positivos/patologia , Proliferação de Células/efeitos dos fármacos , Diabetes Mellitus Experimental/tratamento farmacológico , Diabetes Mellitus Experimental/patologia , Ginsenosídeos/farmacologia , Tolerância Imunológica/efeitos dos fármacos , Imunossupressores/farmacologia , Interferon gama/sangue , Interleucina-2/sangue , Camundongos , Baço/efeitos dos fármacos , Baço/patologia
10.
Ann Clin Lab Sci ; 43(2): 126-34, 2013.
Artigo em Inglês | MEDLINE | ID: mdl-23694786

RESUMO

BACKGROUND: Hepcidin is a central regulator of iron metabolism. As hepcidin is produced mainly by hepatocytes, pathologic changes in the liver may affect hepcidin production. Abnormal hepcidin expression has been reported following liver injury, including liver cirrhosis, alcoholic liver disease, and chronic hepatitis B and hepatitis C. However, it is unclear whether there is a dose-dependent relationship between hepcidin expression and hepatitis B virus load. The aim of this study was to characterize hepcidin levels in patients with different hepatitis B virus (HBV) DNA levels. METHODS: We investigated serum hepcidin levels in 71 patients with different HBV DNA loads, 10 patients with hepatocelluar carcinoma (HCC), and 13 healthy individuals. The relationships between hepcidin expression and hematological/liver functional parameters, iron, and inflammatory indicators were also analyzed. RESULTS: Serum IL-6, ferritin, and hepcidin levels were significantly higher in patients with hepatitis B and in HCC patients than in controls (P<0.05), and strong positive correlations were found between hepcidin and ferritin, AST, ALT, GGT, ALP, TBIL, IBIL, and AFU, as well as between log [hepcidin] and log [HBV], respectively. There were no significant differences in hematological parameters, including WBC, Hb, and platelets among hepatitis B patients, nor was a correlation found between hepcidin and any hematological parameters. CONCLUSION: Our results indicate that hepcidin expression is regulated by iron and inflammatory factors in hepatitis B infection patients, and that the virus load can affect hepcidin production.


Assuntos
Peptídeos Catiônicos Antimicrobianos/sangue , Carcinoma Hepatocelular/sangue , Vírus da Hepatite B/metabolismo , Hepatite B/sangue , Neoplasias Hepáticas/sangue , Carcinoma Hepatocelular/virologia , Ferritinas/sangue , Hepatite B/virologia , Hepcidinas , Humanos , Imunoensaio , Interleucina-6/metabolismo , Neoplasias Hepáticas/virologia , Reação em Cadeia da Polimerase Via Transcriptase Reversa , Estatísticas não Paramétricas , Carga Viral
11.
Clin Exp Med ; 11(1): 33-42, 2011 Mar.
Artigo em Inglês | MEDLINE | ID: mdl-20499129

RESUMO

Hepcidin is a key hormone governing mammalian iron homeostasis and may be directly or indirectly involved in the development of most iron deficiency/overload and inflammation-induced anemia. The objective of this study was to investigate the expression of hepcidin in anemia of chronic disease. To characterize serum hepcidin, iron and inflammatory indicators associated with anemia of chronic disease (ACD), we studied ACD, ACD concomitant iron-deficiency anemia (ACD/IDA), pure IDA and acute inflammation (AcI) patients and analyzed the associations between hepcidin levels and inflammation parameters in various types of anemia. Serum hepcidin levels in patient groups were statistically different, from high to low: ACD, AcI > ACD/IDA > the control > IDA. Serum ferritin levels were significantly increased in ACD and AcI patients but were decreased significantly in ACD/IDA and IDA. Elevated serum EPO concentrations were found in ACD, ACD/IDA and IDA patients but not in AcI patients and the controls. A positive correlation between hepcidin and IL-6 levels only existed in ACD/IDA, AcI and the control groups. A positive correlation between hepcidin and ferritin was marked in the control group, while a negative correlation between hepcidin and ferritin was noted in IDA. The significant negative correlation between hepcidin expression and reticulocyte count was marked in both ACD/IDA and IDA groups. All of these data demonstrated that hepcidin might play role in pathogenesis of ACD, ACD/IDA and IDA, and it could be a potential marker for detection and differentiation of these anemias.


Assuntos
Anemia Ferropriva/patologia , Peptídeos Catiônicos Antimicrobianos/biossíntese , Doença Crônica , Expressão Gênica , Adulto , Idoso , Feminino , Ferritinas/sangue , Hepcidinas , Humanos , Interleucina-6/sangue , Masculino , Pessoa de Meia-Idade , Contagem de Reticulócitos , Estatística como Assunto
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA